Walter & Keenan Financial Consulting Co. MI ADV cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,270 shares of the biopharmaceutical company’s stock after selling 830 shares during the quarter. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Gilead Sciences were worth $373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. lifted its position in Gilead Sciences by 1.4% in the first quarter. BlackRock Inc. now owns 105,236,053 shares of the biopharmaceutical company’s stock worth $7,933,746,000 after purchasing an additional 1,438,806 shares during the period. Bank of New York Mellon Corp lifted its position in Gilead Sciences by 11.6% in the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after purchasing an additional 3,221,439 shares during the period. Sanders Capital LLC lifted its position in Gilead Sciences by 7.0% in the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after purchasing an additional 696,200 shares during the period. Boston Partners lifted its position in Gilead Sciences by 3.1% in the second quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after purchasing an additional 245,805 shares during the period. Finally, OppenheimerFunds Inc. lifted its position in Gilead Sciences by 0.8% in the first quarter. OppenheimerFunds Inc. now owns 7,015,471 shares of the biopharmaceutical company’s stock worth $528,896,000 after purchasing an additional 57,598 shares during the period. 78.04% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have issued reports on the company. Wells Fargo & Co upped their price target on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 26th. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a report on Thursday, July 26th. Mizuho set a $94.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a report on Wednesday, July 18th. Finally, Morgan Stanley upped their price target on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a report on Thursday, July 26th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $88.30.

NASDAQ:GILD traded down $0.74 during trading hours on Friday, reaching $73.38. The company’s stock had a trading volume of 4,912,889 shares, compared to its average volume of 6,022,709. The stock has a market capitalization of $95.89 billion, a PE ratio of 8.57, a P/E/G ratio of -5.64 and a beta of 1.02. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The firm had revenue of $5.65 billion during the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the company posted $2.56 earnings per share. Gilead Sciences’s revenue for the quarter was down 20.9% on a year-over-year basis. sell-side analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total transaction of $3,892,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $238,825,271.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 150,000 shares of company stock valued at $11,141,000 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: What are Closed-End Mutual Funds?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.